<DOC>
	<DOCNO>NCT02598128</DOCNO>
	<brief_summary>Protocol ALCT-0000497 multicenter safety , tolerability fat absorption study anticipate enrol 35 male female subject ( pediatric adult ) cystic fibrosis . Subjects confirm exocrine pancreatic insufficiency use novel enteral feed in-line digestive enzyme cartridge ( RELiZORB ) connect enteral pump set .</brief_summary>
	<brief_title>Safety , Tolerability Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge ( Relizorb )</brief_title>
	<detailed_description>Protocol ALCT-0000497 consist three distinct study period follow : 1 . In Period A ( 7 day ) , subject receive Peptamen 1.5 enteral feeding home . 2 . In Period B ( 11 day ) , subject randomize either Group A ( active investigational placebo control ) Group B ( placebo control active investigational ) receive Impact Peptide 1.5 Days 1 9 . During 8-day washout period Days 1 9 , subject receive Peptamen 1.5 . 3 . In Period C ( 9 day ) , subject use RELiZORB nocturnal enteral feeding Impact Peptide 1.5 .</detailed_description>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>1 . Confirmed CF diagnosis 2 clinical feature 2 . Documented history EPI 3 . Enteral formula use minimum 4x/week 4 . Written inform consent assent , applicable 1 . Uncontrolled diabetes mellitus 2 . Signs symptoms liver cirrhosis portal hypertension 3 . Lung/liver transplant 4 . Active cancer currently receive cancer treatment 5 . Crohn 's celiac disease , infectious gastroenteritis , sprue , lactose intolerant , inflammatory bowel disease 6 . DIOS fibrosing colonopathy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>